COR logo Cencora +
Cencora
+

Cencora (COR) Business News

Track Cencora in real time with a live news feed covering Cencora stock news, official press releases, company announcements, and an archive of historical Cencora news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

Cencora Reports Fiscal 2026 Third Quarter Results

Business Wire

6:30 AM | Wednesday | Aug 5, 2026

news photo
Loading...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 third quarter ended June 30, 2026, revenue increased 5.1 percent year-over-year to $84.8 billion.
On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.94 for the third quarter of fiscal 2026 compared to $3.52 in the prior year third quarter.
Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, inc.

Read full article redirect
6:30 AM | Wednesday | Aug 5, 2026

Cencora Reports Fiscal 2026 Third Quarter Results

Business Wire

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 third quarter ended June 30, 2026, revenue increased 5.1 percent year-over-year to $84.8 billion.
On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.94 for the third quarter of fiscal 2026 compared to $3.52 in the prior year third quarter.
Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, inc.

Read full article arrow
News Thumbnail
11:35 AM | Monday | Aug 3, 2026

Kultura Brands Reports Strong Commercial Momentum Following Successful Participation at Cencora ThoughtSpot 2026

Accesswire

Company Advances Strategic Pharmacy Relationships, Expands Commercial Pipeline and Positions for Continued Growth Across the Healthcare Marketplace JACKSON, WY / ACCESS Newswire / August 3, 2026 / Kultura Brands, Inc. (OTCID:LTNC) today announced the successful completion of its participation at Cencora ThoughtSpot 2026, where the Company strengthened strategic relationships, expanded its commercial pipeline and advanced multiple initiatives designed to support the continued growth of its healthcare platform. ThoughtSpot is one of the independent pharmacy industry's premier annual events, bringing together pharmacy owners, healthcare professionals, manufacturers, suppliers and industry leaders from across the country.

Read full article arrow
News Thumbnail
4:30 PM | Wednesday | Jul 1, 2026

Cencora Announces Date and Time for Third Quarter Fiscal 2026 Earnings Release

Business Wire

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2026 on Wednesday, August 5, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m.
ET on August 5, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer Eva C. Boratto, Executive Vice President & Chief.

Read full article arrow
News Thumbnail
8:00 AM | Wednesday | Jun 17, 2026

Cencora Launches Next-Generation Nucleus® Solution with Multi-Site Pilot Across Specialty Physician Practices

Business Wire

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global pharmaceutical solutions company, today announced a multi-site pilot of its enhanced Nucleus® inventory management solution, designed to help specialty physician practices manage increasingly complex medication workflows with greater efficiency, visibility and control. Developed with input from customer advisory boards and specialty care providers, the updated platform combines redesigned physical infrastructure with software and interface e.

Read full article arrow
News Thumbnail
4:15 PM | Monday | Jun 15, 2026

Cencora Announces Samantha Hammock as Chief Human Resources Officer

Business Wire

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that Silvana Battaglia, Executive Vice President and Chief Human Resources Officer (CHRO), has announced she will retire from the company following a distinguished seven-year tenure. She will be succeeded by Samantha (Sam) Hammock, who will join Cencora as Executive Vice President and CHRO, effective July 13, 2026. "During her seven years of leadership, Silvana has made critical, lasting contributions to Cencora durin.

Read full article arrow
News Thumbnail
10:00 AM | Thursday | Jun 4, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR

PRNewsWire

NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. ("Cencora" or the "Company") (NYSE: COR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Read full article arrow
News Thumbnail
4:57 PM | Tuesday | Jun 2, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR

GlobeNewsWire

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. (“Cencora” or the “Company”) (NYSE: COR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.

Read full article arrow
News Thumbnail
8:00 AM | Tuesday | Jun 2, 2026

Cencora to Support U.S. Distribution of Kite's CAR T-Cell Therapies

Business Wire

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora today announced an agreement with Kite, a Gilead Company, to support the distribution of Kite's U.S. Food and Drug Administration (FDA)-approved CAR T-cell therapies, Yescarta® (axicabtagene ciloleucel) and Tecartus® (brexucabtagene autoleucel). The collaboration is designed to support efficient access to the cell therapies at the increasing number of authorized treatment centers in the U.
S., including health systems and community oncology practices.

Read full article arrow
News Thumbnail
10:21 AM | Thursday | May 28, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR

PRNewsWire

NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. ("Cencora" or the "Company") (NYSE: COR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Read full article arrow
News Thumbnail
6:55 AM | Wednesday | May 27, 2026

Cencora Appoints Eva Boratto as Executive Vice President and Chief Financial Officer

Business Wire

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer of the Company, effective June 29, 2026. Ms.
Boratto succeeds James F. Cleary, who will be retiring from his role as Executive Vice President and Chief Financial Officer as previously announced. Mr. Cleary will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition. Ms.
Boratto is an experienced pub.

Read full article arrow
News Thumbnail